Prognostic Value of Measurable Residual Disease After Venetoclax and Decitabine in AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Prognostic Value of Measurable Residual Disease After Venetoclax and Decitabine in Acute Myeloid Leukemia
Blood Adv 2021 Apr 13;5(7)1876-1883, A Maiti, CD DiNardo, SA Wang, J Jorgensen, TM Kadia, NG Daver, NJ Short, M Yilmaz, N Pemmaraju, G Borthakur, P Bose, GC Issa, A Ferrajoli, EJ Jabbour, N Jain, G Garcia-Manero, M Ohanian, K Takahashi, G Montalban-Bravo, L Masarova, JA Burger, PA Thompson, S Verstovsek, K Sasaki, M Andreeff, CR Rausch, KS Montalbano, S Pierce, W Qiao, J Ning, HM Kantarjian, MY Konopleva, F RavandiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.